Show simple item record

dc.contributor.authorSheng, Zhi
dc.contributor.authorWang, Shu-Zong
dc.contributor.authorGreen, Michael R.
dc.date2022-08-11T08:10:16.000
dc.date.accessioned2022-08-23T17:01:54Z
dc.date.available2022-08-23T17:01:54Z
dc.date.issued2009-02-21
dc.date.submitted2011-04-19
dc.identifier.citationEMBO J. 2009 Apr 8;28(7):866-76. Epub 2009 Feb 19. <a href="http://dx.doi.org/10.1038/emboj.2009.35">Link to article on publisher's site</a>
dc.identifier.issn0261-4189 (Linking)
dc.identifier.doi10.1038/emboj.2009.35
dc.identifier.pmid19229297
dc.identifier.urihttp://hdl.handle.net/20.500.14038/44107
dc.description.abstractLipocalin 24p3 is a secreted protein that can induce apoptosis in cells containing the 24p3 cell surface receptor, 24p3R. The oncoprotein BCR-ABL activates 24p3 and represses 24p3R expression. Thus, BCR-ABL(+) cells synthesise and secrete 24p3, which induces apoptosis in normal 24p3R-containing cells but not in BCR-ABL(+) cells. The cell signalling and transcription factor pathways by which BCR-ABL misregulates expression of 24p3 and 24p3R remain to be elucidated. Here we show that BCR-ABL upregulates 24p3 expression through activation of the JAK/STAT pathway, which culminates in binding of Stat5 to the 24p3 promoter. We find that 24p3R expression is regulated by Runx transcription factors, and that BCR-ABL induces a switch in binding from Runx3, an activator of 24p3R expression, to Runx1, a repressor of 24p3R expression, through a Ras signalling pathway. Finally, we show that repression of 24p3R by BCR-ABL is a critical feature of the mechanism by which imatinib kills BCR-ABL(+) cells. Our results reveal diverse signalling/transcription pathways that regulate 24p3 and 24p3R expression in response to BCR-ABL and are directly relevant to the treatment of BCR-ABL(+) disease.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=19229297&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670863/pdf/emboj200935a.pdf
dc.subjectAnimals
dc.subjectCore Binding Factor Alpha 2 Subunit
dc.subjectDown-Regulation
dc.subjectFemale
dc.subjectFusion Proteins, bcr-abl
dc.subjectHumans
dc.subjectLipocalins
dc.subjectMale
dc.subjectMice
dc.subjectMice, Inbred Strains
dc.subjectMice, SCID
dc.subjectPiperazines
dc.subjectPromoter Regions, Genetic
dc.subjectProto-Oncogene Proteins p21(ras)
dc.subjectPyrimidines
dc.subjectReceptors, Cell Surface
dc.subject*Signal Transduction
dc.subject*Transcription, Genetic
dc.subjectGenetics and Genomics
dc.titleTranscription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R
dc.typeJournal Article
dc.source.journaltitleThe EMBO journal
dc.source.volume28
dc.source.issue7
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/pgfe_pp/81
dc.identifier.contextkey1946736
html.description.abstract<p>Lipocalin 24p3 is a secreted protein that can induce apoptosis in cells containing the 24p3 cell surface receptor, 24p3R. The oncoprotein BCR-ABL activates 24p3 and represses 24p3R expression. Thus, BCR-ABL(+) cells synthesise and secrete 24p3, which induces apoptosis in normal 24p3R-containing cells but not in BCR-ABL(+) cells. The cell signalling and transcription factor pathways by which BCR-ABL misregulates expression of 24p3 and 24p3R remain to be elucidated. Here we show that BCR-ABL upregulates 24p3 expression through activation of the JAK/STAT pathway, which culminates in binding of Stat5 to the 24p3 promoter. We find that 24p3R expression is regulated by Runx transcription factors, and that BCR-ABL induces a switch in binding from Runx3, an activator of 24p3R expression, to Runx1, a repressor of 24p3R expression, through a Ras signalling pathway. Finally, we show that repression of 24p3R by BCR-ABL is a critical feature of the mechanism by which imatinib kills BCR-ABL(+) cells. Our results reveal diverse signalling/transcription pathways that regulate 24p3 and 24p3R expression in response to BCR-ABL and are directly relevant to the treatment of BCR-ABL(+) disease.</p>
dc.identifier.submissionpathpgfe_pp/81
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentPrograms in Gene Function and Expression
dc.source.pages866-76


This item appears in the following Collection(s)

Show simple item record